Jul. 5 at 9:24 PM
Why I chose
$SRTA over
$TMDX
$TMDX is the proven MedTech leader in organ perfusion with OCS technology, larger scale, stronger margins, and a ~
$2.38B market cap. It’s the “quality compounder” in this space.
$SRTA, on the other hand, is the higher beta transformation story, moving as a vertically integrated transplant services platform combining logistics, clinical recovery, and NRP capabilities.
Why
$SRTA stands out right now:
Stronger growth momentum: Q1 revenue +87% YoY to
$67.4M vs TMDX +21%, showing faster acceleration off a smaller base
Business model pivot: exit of lower-margin segments and shift toward higher-value transplant services and integrated recovery operations
Early profitability inflection: first positive net income (
$2.4M) and improving cash flow profile under new structure
Asymmetric valuation: ~
$468M market cap vs larger peer, giving more operating leverage if execution continues
Structural tailwinds: organ shortage + expansion of machine perfusion and NRP adoption benefiting both, but SRTA has more M&A-driven scalability
Bottom line:
TMDX is the stable leader with proven execution.
SRTA is the higher-risk, higher-torque transformation story with more upside if the turnaround sustains.
Curious how others are splitting this: stability vs optionality?
